Editas Medicine Competitors, Revenue, Alternatives and Pricing
Overview
Estimated Revenue & Financials
- Editas Medicine's estimated annual revenue is currently $25.1M per year.
- Editas Medicine received $50.0M in venture funding in December 2017.
- Editas Medicine's estimated revenue per employee is $155,000
Employee Data
- Editas Medicine has 162 Employees.
- Editas Medicine grew their employee count by 5% last year.
- Editas Medicine currently has 1 job openings.
Editas Medicine Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| Advertise Here | ||||||
#1 | $8.7M | 56 | -12% | N/A | - | N/A |
#2 | $8.7M | 56 | 60% | N/A | - | N/A |
#3 | $16.4M | 106 | 14% | N/A | - | N/A |
#4 | $89.4M | 577 | N/A | N/A | - | N/A |
#5 | $116.9M | 754 | N/A | N/A | - | N/A |
#6 | N/A | 220 | N/A | N/A | - | N/A |
#7 | $15.3M | 99 | -17% | N/A | - | N/A |
#8 | N/A | 94 | N/A | N/A | - | N/A |
#9 | $54.6M | 352 | N/A | N/A | - | N/A |
#10 | $17.2M | 111 | 9% | N/A | - | N/A |
What Is Editas Medicine?
Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals162
Number of Employees
$25.1M
Revenue (est)
1
Current Jobs
5%
Employee Growth %
N/A
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Editas Medicine News
The recent performance of Editas Medicine (NASDAQ:EDIT) stock in the market spoke loud and clear to investors as EDIT saw more than ...
CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today ...
On Friday the shares-rate of the Company Editas Medicine, EDIT Stock exchange NASDAQ, is an exciting player in the Medical.
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
#1 | $16.5M | 162 | N/A | N/A | - | N/A |
#2 | $52.7M | 162 | 11% | N/A | - | N/A |
#3 | $23.5M | 162 | 15% | N/A | - | N/A |
#4 | N/A | 163 | N/A | N/A | - | N/A |
#5 | N/A | 163 | N/A | N/A | - | N/A |
Editas Medicine Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-12-07 | $50.0M | Undisclosed | Morgan Stanley | Article |
Editas Medicine Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2015-04-28 | Vic Myer | Chief Technology Officer | Article |
| 2015-07-02 | Andrew Hack | CFO | Article |
| 2016-01-06 | Timothy D. Hunt | SVP Corporate Affairs | Article |
| 2018-03-30 | James Mullen | Chairman | Article |